- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01129258
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
March 8, 2011 updated by: Pfizer
A Phase 1 Placebo-Controlled Trial to Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Multiple Escalating Oral Doses of PF-04991532 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-04991532 following multiple (14 days) escalating oral doses in patient wtih type 2 diabetes.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Safety/Tolerability, PK, and PD
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Chula Vista, California, United States, 91911
- Pfizer Investigational Site
-
Fountain Valley, California, United States, 92708
- Pfizer Investigational Site
-
-
Florida
-
Miami, Florida, United States, 33169
- Pfizer Investigational Site
-
-
Texas
-
San Antonio, Texas, United States, 78229
- Pfizer Investigational Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with type 2 diabetes mellitus who are taking metformin only. Treatment should be stable, where this is defined as no change in the treatment, including dose, over the past 2 months. Subjects treated with a sulfonylurea (SU) or a dipeptidyl peptidase-4 inhibitor (DPP-4i) in combination with metformin may be eligible if washed off the SU or DPP-4i to metformin only for a minimum of 4 weeks before dosing. Subjects being switched over from an SU and metformin or a DPP-4i and metformin to metformin only will still need to meet the fasting glucose requirements on Day -2 as defined in the protocol.
- Body Mass Index (BMI) of 18.5 to 45.0 kg/m2; and a total body weight >50 kg (110 lbs).
- Fasting C-peptide >0.8 ng/mL.
- HbA1c >/=7% and >/=10%. If the patient requires to be washed off an SU or DPP-4i, the HbA1c limits will be >/=6.5% and </=9%.
Exclusion Criteria:
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease. Subjects who have chronic conditions other than T2DM (for example, hypercholesterolemia or hypertension) but are controlled by either diet or stable (for the last 2 months) doses of medications may be included as well.
- Evidence or history of diabetic complications with significant end-organ damage.
- Any condition possibly affecting drug absorption (eg, gastrectomy).
- History of stroke, transient ischemic attack, or myocardial infarction within the past 6 months.
- History of coronary artery bypass graft or stent implantation.
- Clinically significant peripheral vascular disease.
- Any history or clinical evidence of congestive heart failure, NYHA Classes II-IV.
- Current history of angina/unstable angina.
- ECG findings suggestive of asymptomatic myocardial ischemia or QTc >470 msec at screening.
- One or more self-reported episodes of hypoglycemia within the last 3 months, or two or more self-reported episodes of hypoglycemia within the last 6 months.
- Screening or Day -2 fasting (>/=8 hours) glucose, </=90 or >/=270 mg/dL, confirmed by a single repeat if deemed necessary.
- A positive urine drug screen.
- Use of tobacco or nicotine-containing products in excess of the equivalent of 10 cigarettes per day.
- History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces (360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of screening.
- Certain concomitant medications are excluded, as defined in the protocol.
- Screening supine blood pressure >/=160 mm Hg (systolic) or >/=100 mm Hg (diastolic).
- Certain laboratory values (for example, triglyceride and liver function test results).
- Pregnant or nursing females; females of childbearing potential.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo to match PF-04991532 will be provided.
Subjects will be dosed for 14 days.
In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
|
Experimental: PF-04991532
|
Subjects will be dosed wtih PF-04991532 for 14 days.
The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID).
Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses.
All doses will be administered as tablets (10, 50, and 150 mg strengths).
In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety Endpoints: Safety and tolerability of PF-04991532 will be assessed by physical examinations, adverse event monitoring, 12-lead ECGs, vital sign, and clinical safety laboratory measurements.
Time Frame: 5 months
|
5 months
|
Single-Dose PK Endpoints for PF-04991352: Cmax, Tmax, and AUC(0-tau).
Time Frame: 5 months
|
5 months
|
Multiple-Dose PK Endpoints for PF-04991532: Cmax(ss), Tmax(ss), AUC(0-tau,ss), AUC(0-last), half-life, Cmin(ss), Cav(ss), Ae%, CL/F, Vz/F, CLrenal; accumulation ratios AUC(0-tau,ss)/AUC(0-tau,sd) and Cmax(ss)/Cmax(sd), as the data permit.
Time Frame: 5 months
|
5 months
|
PD Endpoint: glucose excursion (change from Day -1 baseline) in response to a liquid meal test (MMTT) on Days 1 and 14.
Time Frame: 5 months
|
5 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Insulin and C-peptide (changes from Day -1 baseline) during an MMTT on Days 1 and 14.
Time Frame: 5 months
|
5 months
|
Mean daily glucose (change from Day -1 baseline) on Days 1 and 14.
Time Frame: 5 months
|
5 months
|
Fasting plasma glucose (change from Day -1 baseline) on Days 1, 3, 6, 10, and 14.
Time Frame: 5 months
|
5 months
|
Lipids (change from Day -1 baseline), including: TG, TC, HDL-cholesterol, LDL-cholesterol, FFA, beta-OHB, and ACAC, at times specified in the SOA.
Time Frame: 5 months
|
5 months
|
Lactate (change from Day -1 baseline), at times specified in the SOA.
Time Frame: 5 months
|
5 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2010
Primary Completion (Actual)
December 1, 2010
Study Completion (Actual)
December 1, 2010
Study Registration Dates
First Submitted
May 21, 2010
First Submitted That Met QC Criteria
May 21, 2010
First Posted (Estimate)
May 24, 2010
Study Record Updates
Last Update Posted (Estimate)
March 9, 2011
Last Update Submitted That Met QC Criteria
March 8, 2011
Last Verified
March 1, 2011
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2611004
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glucose Metabolism Disorders
-
University of AberdeenCompletedMetabolism Disorder, GlucoseUnited Kingdom
-
Columbia UniversityCompletedMetabolism Disorder, GlucoseUnited States
-
University of LeipzigInstitut für Gesundheits- und Praxismanagement GmbHWithdrawn
-
Purdue UniversityAlmond Board of CaliforniaActive, not recruitingGlucose Intolerance | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of Missouri-ColumbiaCompletedGlucose | Blood Sugar; High | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
University of South CarolinaCompletedPhysical Activity | Sedentary Lifestyle | Metabolism Disorder, GlucoseUnited States
-
Solvay PharmaceuticalsTerminatedDyslipidemia | Glucose Metabolism DisorderPoland, Croatia, Finland, France, Germany, Netherlands, Romania, Ukraine
-
DLR German Aerospace CenterCompletedGlucose Metabolism Disorders | Local Glucose Uptake
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderPoland, Ukraine, United Kingdom
-
Solvay PharmaceuticalsCompletedDyslipidemia/Glucose Metabolism DisorderCzech Republic, France, Hungary, India, Lithuania, Poland, Slovakia
Clinical Trials on PF-04991532
-
Danish Head and Neck Cancer GroupRecruitingHypoxia | Head and Neck Squamous Cell Carcinoma | Radiotherapy | Hypoxic Modification | Gene Profile, Gene SignatureDenmark
-
PfizerCompletedDiabetes Mellitus, Type 2United States, Taiwan, Slovakia, Mexico, Canada, Hungary
-
PfizerCompletedDiabetes, Type 2Canada, United States, Korea, Republic of, Taiwan, Mexico, Hungary, Slovakia
-
PfizerCompletedHealthy | Drug InteractionBelgium
-
PfizerCompletedDiabetes Mellitus, Type 2United States, Japan
-
PfizerCompletedHealthyUnited States
-
PfizerCompletedGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes MellitusUnited States
-
PfizerCompleted
-
PfizerCompletedHealthy | Type 2 Diabetes MellitusUnited States